4XC1 Stock Overview A clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
KalVista Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for KalVista Pharmaceuticals Historical stock prices Current Share Price US$8.50 52 Week High US$20.20 52 Week Low US$7.55 Beta 0.86 1 Month Change -2.86% 3 Month Change -15.00% 1 Year Change -17.48% 3 Year Change -22.73% 5 Year Change -37.50% Change since IPO 5.59%
Recent News & Updates
KalVista Pharmaceuticals, Inc. Appoints Jeb Ledell as Chief Operating Officer Dec 16
KalVista Pharmaceuticals, Inc. Appoints Laurence Reid to Board of Directors Nov 26 KalVista Pharmaceuticals, Inc. announced that it expects to receive $5 million in funding from DRI Capital Inc.
Forecast to breakeven in 2027 Nov 05
KalVista Pharmaceuticals, Inc. Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology Oct 29
New major risk - Share price stability Oct 01 See more updates
KalVista Pharmaceuticals, Inc. Appoints Jeb Ledell as Chief Operating Officer Dec 16
KalVista Pharmaceuticals, Inc. Appoints Laurence Reid to Board of Directors Nov 26 KalVista Pharmaceuticals, Inc. announced that it expects to receive $5 million in funding from DRI Capital Inc.
Forecast to breakeven in 2027 Nov 05
KalVista Pharmaceuticals, Inc. Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology Oct 29
New major risk - Share price stability Oct 01
KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema Oct 01
New major risk - Financial position Sep 06
Kalvista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema Sep 03
KalVista Pharmaceuticals, Inc., Annual General Meeting, Oct 03, 2024 Aug 23
KalVista Pharmaceuticals, Inc. Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema Aug 15
No longer forecast to breakeven Jul 16
New minor risk - Profitability Jul 12
KalVista Pharmaceuticals, Inc. Initiates KONFident-KID Trial for On-Demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11 Jun 27
KalVista Pharmaceuticals, Inc. Submits New Drug Application to FDA for Sebetralstat as First Oral On-Demand Treatment for Hereditary Angioedema Jun 18
KalVista Pharmaceuticals, Inc. Presents Data At Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024 Jun 08
Kalvista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema At the European Academy of Allergy and Clinical Immunology (Eaaci) Congress 2024 Jun 05
Kalvista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating Its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema Jun 01
Forecast to breakeven in 2027 May 05
Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors Apr 23 KalVista Pharmaceuticals, Inc. to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas KalVista Pharmaceuticals, Inc. Announces Board Changes
KalVista Pharmaceuticals, Inc. Receives UK Innovation Passport for Sebetralstat from UK Medicines and Healthcare Products Regulatory Agency Feb 22
KalVista Pharmaceuticals, Inc. Receives UK Innovation Passport for Sebetralstat from UK Medicines and Healthcare Products Regulatory Agency Feb 20
CEO & Director recently sold €817k worth of stock Feb 18
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting Feb 17 KalVista Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.
New major risk - Share price stability Feb 14
Kalvista Pharmaceuticals, Inc. Reports Phase 3 Konfident Trial Meets All Endpoints for Sebetralstat as First Oral On-Demand Therapy for Hereditary Angioedema Feb 13
New minor risk - Profitability Dec 10
New major risk - Financial position Dec 08
Kalvista Pharmaceuticals Announces Phase 3 Konfident Trial Milestone Achieved Nov 14
KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology Nov 03
KalVista Pharmaceuticals, Inc., Annual General Meeting, Sep 26, 2023 Aug 15
KalVista Pharmaceuticals, Inc. Appoints Nicole Sweeny as Chief Commercial Officer Jul 26
KalVista Pharmaceuticals, Inc. Presents New Data at 2023 Meeting of the European Academy of Allergy and Clinical Immunology Jun 13
KalVista Pharmaceuticals, Inc. Presents Data At 13Th C1-Inhibitor Deficiency & Angioedema Workshop May 10
KalVista Pharmaceuticals, Inc. Provides Progress Updates on Sebetralstat Development Feb 15
Kalvista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in the Lancet Feb 11
Kalvista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President Jan 06
KalVista Pharmaceuticals Presents Patient-Focused Data at American College of Allergy, Asthma & Immunology (ACAAI) 2022 Meeting Nov 15
Kalvista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema Nov 01
KalVista Pharmaceuticals, Inc. Announces Management Changes Oct 18
KalVista Pharmaceuticals, Inc. Presents New Patient-Centric Data at 2022 HAEi Global Leadership Workshop Oct 08
KalVista Pharmaceuticals Announces Termination of KVD824 Phase 2 KOMPLETE Trial for Prophylactic Treatment of Hereditary Angioedema Oct 05
Kalvista Pharmaceuticals, Inc. Announces Initiation of KONFIDENT-S Open Label Extension Study for Sebetralstat in Hereditary Angioedema Aug 24
KalVista Pharmaceuticals, Inc., Annual General Meeting, Oct 13, 2022 Aug 23
No longer forecast to breakeven Jul 08
KalVista Pharmaceuticals, Inc. Announces Board Changes May 28
KalVista Pharmaceuticals, Inc. Presents Data Showing Rapid Reduction of Plasma Kallikrein Activity After Oral KVD900 Treatment and Early Symptom Relief from HAE Attacks in Patients Mar 02
KalVista Pharmaceuticals, Inc. to Present Data on Oral On-Demand HAE Therapy KVD900 at AAAAI 2022 Feb 03
U.S. Food and Drug Administration Lifts the Clinical Hold on Kalvista Pharmaceuticals, Inc.’s Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema Sep 15
KalVista Pharmaceuticals, Inc. Provides Progress Update on Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema Aug 25
KalVista Pharmaceuticals Presents Data Showing Single On-Demand Treatment with Orally Administered KVD900 Significantly Slows Progression and Accelerates Resolution of Attacks in Patients with HAE Jul 14 KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) dropped from Russell 3000E Value Index
KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop Jun 06
KalVista Pharmaceuticals, Inc. Appoints Nancy Stuart to Board of Directors and Audit Committee Mar 21
Revenue misses expectations Mar 13
KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks Feb 10
New 90-day low: €12.50 Jan 29
Kalvista Pharmaceuticals, Inc. Provides Data on Kvd824 as Twice-Daily Oral Candidate for Prophylactic Treatment of Hae; Announces Novel Oral Factor Xiia Inhibitor Program as the Next Area of Development Focus Dec 13
Revenue misses expectations Dec 12
Kalvista Pharmaceuticals, Inc. Reports Demise of Arnold Oronsky on November 21, 2020 Dec 02
New 90-day high: €16.20 Nov 19
KalVista Pharmaceuticals, Inc. Announces Updated Guidance on the Data Release of Its Phase 2 Clinical Trial Nov 17
New 90-day high: €14.60 Oct 31
KalVista Pharmaceuticals Provides Update on Oral Hereditary Angioedema Franchise Oct 16
New 90-day high: €11.90 Oct 08
New 90-day high - €11.60 Sep 16
First quarter earnings released Sep 16
New 90-day high - €11.50 Aug 22
New 90-day low - €8.55 Jul 30 Shareholder Returns 4XC1 DE Biotechs DE Market 7D 7.6% 1.9% 1.4% 1Y -17.5% -9.8% 9.1%
See full shareholder returns
Return vs Market: 4XC1 underperformed the German Market which returned 7.4% over the past year.
Price Volatility Is 4XC1's price volatile compared to industry and market? 4XC1 volatility 4XC1 Average Weekly Movement 8.5% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 4XC1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4XC1's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial.
Show more KalVista Pharmaceuticals, Inc. Fundamentals Summary How do KalVista Pharmaceuticals's earnings and revenue compare to its market cap? 4XC1 fundamental statistics Market cap €429.60m Earnings (TTM ) -€150.55m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 4XC1 income statement (TTM ) Revenue US$0 Cost of Revenue US$91.00m Gross Profit -US$91.00m Other Expenses US$65.39m Earnings -US$156.39m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/06 20:42 End of Day Share Price 2025/01/06 00:00 Earnings 2024/10/31 Annual Earnings 2024/04/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources KalVista Pharmaceuticals, Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Tazeen Ahmad BofA Global Research null null BTIG Charles Duncan Cantor Fitzgerald & Co.
Show 9 more analysts 
